Structure-activity relationships of heteroaromatic esters as human rhinovirus 3C protease inhibitors

Bioorganic and Medicinal Chemistry Letters

Volumn 19, Issue 13, 2009, Pages 3632-3636

  Im, Isak ^a   Lee, Eui Seung ^b   Choi, Soo Jeong ^a   Lee, Ju Yeon ^a   Kim, Yong Chul ^a  

^a Gwangju Institute of Science and Technology (GIST)   (South Korea)

^b Chonnam National University Medical School   (South Korea)

Author keywords

3C Protease; Heteroaromatic esters; Inhibitors; Rhinovirus

Indexed keywords

ESTER DERIVATIVE; HETEROCYCLIC COMPOUND; HUMAN RHINOVIRUS 3C PROTEASE INHIBITOR; PROTEINASE INHIBITOR; UNCLASSIFIED DRUG;

ARTICLE; DRUG POTENCY; DRUG STRUCTURE; DRUG SYNTHESIS; HUMAN RHINOVIRUS; IC 50; MOLECULAR DOCKING; NONHUMAN; PROTEINASE INHIBITION; REACTION ANALYSIS; STRUCTURE ACTIVITY RELATION; STRUCTURE ANALYSIS;

ANTIVIRAL AGENTS; COMPUTER SIMULATION; CYSTEINE ENDOPEPTIDASES; CYSTEINE PROTEINASE INHIBITORS; FURANS; HUMANS; PYRIDINES; RHINOVIRUS; STRUCTURE-ACTIVITY RELATIONSHIP; VIRAL PROTEINS; VIRUS REPLICATION;

HUMAN RHINOVIRUS 3; RHINOVIRUS;

EID: 66349118846     PISSN: 0960894X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bmcl.2009.04.114     Document Type: Article

References (32)

1. Couch R.B. In: Fields B.N., Knipe D.M., Howley P.M., Chanock R.M., Monath T.P., Melnick J.L., and Roizman B. (Eds). Fields Virology. 3rd ed. Vol. 1 (1996), Lippincott-Raven, Philadelphia 713 Chapter 23
2. McKinlay M.A., Pevear D.C., and Rossmann M.G. Annu. Rev. Microbiol. 46 (1992) 635
3. Phillpotts R.J., and Tyrrell D.A.J. Br. Med. Bull. 41 (1985) 386
4. Gwaltney J.M. In: Mandell G.L., Douglas R.G., and Bennett J.E. (Eds). Principles and Practices of Infectious Diseases (1985), John Wiley & Sons, New York 351 Chapter 38
5. Gwaltney J.M. In: Evans A.S. (Ed). Viral Infections of Humans (1982), Plenum, New York 491 Chapter 20
6. Rueckert R.R. In: Fields B.N., Knipe D.M., Howley P.M., Chanock R.M., Monath T.P., Melnick J.L., and Roizman B. (Eds). Fields Virology. 3rd ed. Vol. 1 (1996), Lippincott-Raven, Philadelphia 609 Chapter 21
7. Kräusslich H.-G., and Wimmer E. Annu. Rev. Biochem. 57 (1988) 701
8. Phillpotts R.J., and Tyrrell D.A. Br. Med. Bull. 41 (1985) 386
9. Guiles J.W. Exp. Opin. Ther. Pat. 7 (1997) 123
10. Wang Q.M. Prog. Drug. Res. 52 (1999) 197
11. Wang Q.M., and Chen S.H. Curr. Protein Pept. Sci. 8 (2007) 19
12. Leong L.E.C., Walker P.A., and Porter A.G. J. Biol. Chem. 268 (1993) 25735
13. Matthews D.A., Smith W.W., Ferre R.A., Condon B., Budahazi G., Sisson W., Villafranca J.E., Janson C.A., McElroy H.E., Gribskov C.L., and Worland S. Cell 77 (1994) 761
14. Witherell G. Curr. Opin. Investig. Drugs 1 (2000) 297
15. Dragovich P.S. Exp. Opin. Ther. Pat. 11 (2001) 177
16. Leung-Toung R., Zhao Y., Li W., Tam T.F., Karimian K., and Spino M. Curr. Med. Chem. 13 (2006) 547
17. Hayden F.G., Turner R.B., Gwaltney J.M., Chi-Burris K., Gersten M., Hsyu P., Patick A.K., Smith Iii G.J., and Zalman L.S. Antimicrob. Agents. Chemother. 47 (2003) 3907
18. Dragovich P.S., Prins T.J., Zhou R., Johnson T.O., Hua Y., Luu H.T., Sakata S.K., Brown E.L., Maldonado F.C., Tuntland T., Lee C.A., Fuhrman S.A., Zalman L.S., Patick A.K., Matthews D.A., Wu E.Y., Guo M., Borer B.C., Nayyar N.K., Moran T., Chen L., Rejto P.A., Rose P.W., Guzman M.C., Dovalsantos E.Z., Lee S., McGee K., Mohajeri M., Liese A., Tao J., Kosa M.B., Liu B., Batugo M.R., Gleeson J.P.R., Wu Z.P., Liu J., Meador Iii J.W., and Ferre R.A. J. Med. Chem. 46 (2003) 4572
19. Reich S.H., Johnson T., Wallace M.B., Kephart S.E., Fuhrman S.A., Worland S.T., Matthews D.A., Hendrickson T.F., Chan F., Meador Iii J., Ferre R.A., Brown E.L., DeLisle D.M., Patick A.K., Binford S.L., and Ford C.E. J. Med. Chem. 43 (2000) 1670
20. Hamdouchi C., Sanchez-Martinez C., Gruber J., Del Prado M., Lopez J., Rubio A., and Heinz B.A. J. Med. Chem. 46 (2003) 4333
21. Maugeri C., Alisi M.A., Apicella C., Cellai L., Dragone P., Fioravanzo E., Florio S., Furlotti G., Mangano G., Ombrato R., Luisi R., Pompei R., Rincicotti V., Russo V., Vitiello M., and Cazzolla N. Bioorg. Med. Chem. 16 (2008) 3091
22. Anand K., Ziebuhr J., Wadhwani P., Mesters J.R., and Hilgenfeld R. Science 300 (2003) 1763
23. Ghosh A.K., Xi K., Grum-Tokars V., Xu X., Ratia K., Fu W., Houser K.V., Baker S.C., Johnson M.E., and Mesecar A.D. Bioorg. Med. Chem. Lett. 17 (2007) 5876
24. Blanchard J.E., Elowe N.H., Huitema C., Fortin P.D., Cechetto J.D., Eltis L.D., and Brown E.D. Chem. Bio. 11 (2004) 1445
25. Kuo C.J., Liu H.G., Lo Y.K., Seong C.M., Lee K.I., Jung Y.S., and Liang P.H. FEBS Lett. 583 (2009) 549
26. Zhang J., Pettersson H.I., Huitema C., Niu C., Yin J., James M.N.G., Eltis L.D., and Vederas J.C. J. Med. Chem. 50 (2007) 1850
27. Ghosh A.K., Gong G., Grum-Tokars V., Mulhearn D.C., Baker S.C., Coughlin M., Prabhakar B.S., Sleeman K., Johnson M.E., and Mesecar A.D. Bioorg. Med. Chem. Lett. 18 (2008) 5684
28. Huitema C., Zhang J., Yin J., James M.N.G., Vederas J.C., and Eltis L.D. Bioorg. Med. Chem. 16 (2008) 5761
29. Lam P.Y.S., Clark C.G., Saubern S., Adams J., Winters M.P., Chan D.M.T., and Combs A. Tetrahedron Lett. 39 (1998) 2941
30. Nolt M.B., Smiley M.A., Varga S.L., McClain R.T., Wolkenberg S.E., and Lindsley C.W. Tetrahedron 62 (2006) 4698
31. pro was purified using the IMPACT-CN system (New England Biolabs, Beverly, MA). A protease stock solution was maintained in 20 mM HEPES/NaOH, 100 mM NaCl, 1 mM EDTA, and 1 mM dithiothreitol (pH 7.9).
32. 50 values of six potent inhibitors were determined using various concentrations with three independent experiments.